PURPOSE: To investigate chemosensitivity with an @entity855 -based chemotherapy response assay in @entity1 with @entity43 according to @entity5 histology, grade, and disease status. MATERIALS AND METHODS: One hundred specimens were collected during primary or secondary debulking from 67 @entity1 with primary @entity43 , 24 @entity1 with recurrent @entity43 , 5 @entity1 with primary @entity3906 , and 4 @entity1 with recurrent @entity3906 ; samples were collected between August 2006 and June 2009. @entity5 cells were isolated and cultured for 48 hours in media containing chemotherapy. The chemosensitivity index (CI) was calculated as 300 minus the sum of the cell death rate at 0.2 , 1 , and 5  drug concentrations, and the CI values were compared. RESULTS: CI values were obtained from 93 of 100 @entity1 . The most active agents against @entity66 were @entity1260 and @entity1311 . For primary @entity420 , @entity1311 and @entity2600 were the most active, followed by @entity1260 . For @entity1358 , @entity1260 was the most active, followed by @entity1311 and @entity2600 . Although not statistically significant, the CIs of @entity900 , @entity3003 , @entity1311 , and @entity1205 decreased as @entity5 grade increased. In 14 cases of recurrent disease, @entity1311 was the most active, followed by @entity1260 and @entity900 . CONCLUSION: @entity1260 and @entity1311 were the most active drugs for primary and recurrent disease. Therefore, we recommend further clinical studies to confirm the efficacy of @entity1311 , @entity1260 , and @entity900 combination chemotherapy for recurrent and primary @entity43 .

XXXX -Based Chemotherapy Response Assay in Primary or Recurrent @entity43 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'epithelial ovarian or peritoneal cancer'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity66 :: ('MESH:D004194', 'Disease') :: ['primary disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity3906 :: ('MESH:D010534', 'Disease') :: ['peritoneal cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['clear cell carcinoma'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['Ifosfamide', 'ifosfamide'] @entity420 :: ('MESH:D000230', 'Disease') :: ['serous adenocarcinoma'] @entity855 :: ('MESH:D000255', 'Chemical') :: ['adenosine triphosphate']
@entity855 :: (MESH:D000255,Chemical) :: ['ATP']
